SNT 0.00% 3.0¢ syntara limited

YAWN, page-46

  1. 5,943 Posts.
    lightbulb Created with Sketch. 103
    Nothing to go for at the moment. In fact the delay in patient recruitment for the Bronchitol trial in the US is bad news. Plus it seems from the notes that Pharmaxis is on the hook for $3m of costs (more to come ??) on that trial.

    Unless something comes left field, this could be heading back to 22-23c.
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.